|Bid||25.44 x 1300|
|Ask||26.24 x 1100|
|Day's Range||25.17 - 26.26|
|52 Week Range||13.19 - 76.10|
|Beta (5Y Monthly)||0.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec 06, 2022 - Dec 12, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.92|
Subscribe to Yahoo Finance Plus to view Fair Value for PHR
The average of price targets set by Wall Street analysts indicates a potential upside of 25.7% in Phreesia (PHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
WILMINGTON, Del., September 22, 2022--Phreesia, a leader in patient intake, outreach and activation, has named Alexandra Beneville as Vice President of Life Sciences Content Strategy. Beneville officially joined Phreesia on Aug. 1, 2022, from Phosphorus, a direct-to-consumer genomic testing company, where she had served as Vice President of Marketing since December 2021.
WILMINGTON, Del., September 16, 2022--Phreesia is proud to announce that Zeeshan Butt, PhD, a Director of Clinical Content, has been selected to serve a three-year term as a member of the National Quality Forum (NQF)’s Measure Applications Partnership (MAP) 2022-2023 Clinician Workgroup.